Search
EHA-SWG Scientific Meeting on Integrated Diagnosis Strategies in Oncohematology for the Management of Cytopenias and Leukocytosis
Dates: February 8-10, 2018
Location: Barcelona, Spain
Chair: MC Béné
Co-chair: G Zini
Organized by: EHA & the EHA Scientific Working Group on Diagnosis: Morphology and Flow Cytometry
After a successful first edition in 2015, this meeting returns to Barcelona on February 8-10, 2018.…
EHA-SWG Scientific Meeting on Immunotherapy for Hematological Disorders
EHA and the Scientific Working Group on Immunotherapy for Hematological Disorders are happy to announce the redesigned fully virtual meeting program to meet the needs of hematologists and immunologists in these challenging times.
Read moreEHA Pediatric Course 2019
Dates: April 3-6, 2019
Location: Hotel Riviera, Sorrento, Italy
Pediatric Hemato-Oncology is a very specialized branch of hematology.
“Nothing about us without us”: how patient advocacy is changing the game
Nuno Borges MBBS MRes, on behalf of YoungEHA
When it comes to advancing medical care, there is no denying that patients are at the core of everything we do.
Myelodysplastic Syndromes (MDS)
The SWG on Myelodysplastic Syndromes (MDS) focuses on the promotion and exchange of scientific and clinical evidence, ideas and projects in the field of MDS.
Read moreHighlights from the SWG
Events
The ERIC International Preceptorship, Realizing Precision Medicine in CLL: Why and How
Stresa, Italy
November 17–18, 2023
PublicationsRecent ERIC publications include:
The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia
Other malignancies in the history of CLL: an international multicenter study conducted…
EHA Congratulates the 2021 Bilateral Collaborative Grant Winners
The Hague, April 25, 2022 –EHA congratulates four talented researchers in Hematology on their receipt of the inaugural EHA Bilateral Collaborative Grants 2021 after a rigorous selection process.
Read moreABT-199: Novel Bcl-2 specific inhibitor updated results confirm substantial activity and durable responses in high-risk CLL.
Chronic Lymphocytic Leukaemia (CLL) is the most common leukemia in adults in the Western world and is diagnosed in approximately 5 persons per 100,000 population per year.
Read more